^
Association details:
| Biomarker: | MLL rearrangement |
|---|---|
| Cancer: | Leukemia |
| Drug: | D0060-319 (Menin-MLL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Examination of in vitro and in vivo antitumor activity of Menin-MLL inhibitor, D0060-319.
Published date:
05/25/2023
Excerpt:
In the MV4-11 cell mouse xenograft tumor model, D0060-319 significantly inhibited tumor growth at the dose of 25mg/kg, with a tumor growth inhibition (TGI) rate of 82.97%, and other doses (50, 75 and 100mg/kg) tumor completely regressed...In MLL-rearranged leukemia, D0060-319 showed high antitumor activity and good tolerability both in vitro and in vivo.
DOI:
10.1200/JCO.2023.41.16_suppl.e15119
